<DOC>
<DOCNO>1050331_business_story_4555575.utf8</DOCNO>
<TEXT>


The Telegraph - Calcutta : Business

 Strides strikes deal with US firm

 OUR SPECIAL CORRESPONDENT 

 Mumbai, March 30: Strides Arcolab has inked a deal with a US hospital company under which it will develop, license and manufacture four specialised injectable products to be sold in the US market.

 The size of the contract is estimated to be $90 million at the lower end and $160 million at the upper end, including milestone payments, the company informed the Bombay Stock Exchange today.

 Initially, the contract is for five years, which can be renewed later. 

 Regulatory filings for these products are expected early next year while the licensed products will be available in the US market from 2007. 

 Strides group CEO Arun Kumar said, ?The success of this strategic relationship will increase the credibility of Strides? partnering philosophy.?

 The deal sparked a rally in the Strides Arcolab stock on Dalal Street today. The scrip opened at Rs 187.20 and hit an intra-day high of Rs 205.40. It finally posted an 8 per cent increase, or Rs 15.05, to close at Rs 202.30.

 Strides Arcolab, which manufactures a wide range of medicines, over-the-counter products and nutraceuticals, has a global presence in more than 50 countries. 

 The company has units in India, Brazil, Mexico and the US. It also supplies to a number of geographic locations, including Latin America, the UK, Southeast Asia, Africa, Australia and Russia. 

 Earlier, Strides had entered into an agreement with Mayne Pharm Business Unit of Australia-based Mayne Group Ltd to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets. 




</TEXT>
</DOC>